bluuebunny/crossref_metadata_2025 huggingface dataset:
Estrogen dependence of HCI-013 PDX tumor from Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts
Authors: Bieniasz Magdalena , Radhakrishnan Parvathi , Faham Najme , De La O Jean-Paul , Welm Alana L.
Published: April 2023

Graph represents orthotopic HCI-013 tumor growth rate in NOD/SCID mice. Tumor growth rate was assessed weekly in mice with and without implantation of beeswax E2 pellets vs. ovariectomized mice with and without implantation of beeswax E2 pellets. In mice with ovaries supplemented with estrogen released from beeswax E2 pellet, removal of the pellet after 13 weeks resulted in immediate tumor shrinkage. ER+ breast PDX models can be used to dissect estrogen dependence/endocrine resistance.
Data Supplement from Activating FGFR2–RAS–BRAF Mutations in Ameloblastoma
Authors: Brown Noah A. , Rolland Delphine , McHugh Jonathan B. , Weigelin Helmut C. , Zhao Lili , Lim Megan S. , Elenitoba-Johnson Kojo S.J. , Betz Bryan L.
Published: April 2023

Supplemental Table S2. Non-ameloblastoma odontogenic tumor BRAF V600E allele-specific PCR.
Supplementary Table 5 from Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer
Authors: Sanz-Pamplona Rebeca , Lopez-Doriga Adriana , Paré-Brunet Laia , Lázaro Kira , Bellido Fernando , Alonso M. Henar , Aussó Susanna , Guinó Elisabet , Beltrán Sergi , Castro-Giner Francesc , Gut Marta , Sanjuan Xavier , Closa Adria , Cordero David , Morón-Duran Francisco D. , Soriano Antonio , Salazar Ramón , Valle Laura , Moreno Victor
Published: April 2023

Mutations validated in Biomark platform (Fluidigm) and by Sanger Sequencing.
Supplementary Figure 1 from Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Authors: Tarlock Katherine , Alonzo Todd A. , Gerbing Robert B. , Raimondi Susana C. , Hirsch Betsy A. , Sung Lillian , Pollard Jessica A. , Aplenc Richard , Loken Michael R. , Gamis Alan S. , Meshinchi Soheil
Published: April 2023

Outcomes for FLT3/ITD patients in the No-GO and GO cohorts who did not receive HCT. (A) RR and (B) DFS.
Supplementary Figure 1 and Tables 1-8 from Pretreatment microRNA Expression Impacting on Epithelial-to-Mesenchymal Transition Predicts Intrinsic Radiosensitivity in Head and Neck Cancer Cell Lines and Patients
Authors: de Jong Monique C. , ten Hoeve Jelle J. , Grénman Reidar , Wessels Lodewyk F. , Kerkhoven Ron , te Riele Hein , van den Brekel Michiel W.M. , Verheij Marcel , Begg Adrian C.
Published: April 2023

Supplementary Figure 1 and Tables 1-8. Supplementary figure 1. Heatmap of common response, 2 and 6 hours after irradiation. Heatmap of the common response to 4 Gy irradiation in all 32 cell lines, adapted from the BRB-array tools time course plug-in output. Supplementary table 1 gives an overview of cell line characteristics. Supplementary table 2 describes the patient characteristics for the 34 patients in the validation cohort. Supplementary table 3 describes the references used for the definition of miR functions stated in table 1. Supplementary table 4 lists 1226 genes significantly correlated with radioresistance from a BRB time course plug-in analysis. Supplementary table 5 lists the genes in our p53 and DNA repair signatures. Supplementary table 6 lists the HNSCC EMT-scores for the 32 cell lines. Supplementary table 7 lists the 1189 genes in the HNSCC-EMT signature. Supplementary table 8 shows results of testing gene sets for reactive oxygen species, DNA repair, cell cycle phase and several means of cell death against the EMT gene set.
Supplementary Table S1 from Failures in Phase III: Causes and Consequences
Authors: Seruga Bostjan , Ocana Alberto , Amir Eitan , Tannock Ian F.
Published: April 2023

RCTs with negative primary outcome
Supplementary Methods from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
Authors: Miltiades Paraskevi , Lamprianidou Eleftheria , Vassilakopoulos Theodoros P. , Papageorgiou Sotirios G. , Galanopoulos Athanasios G. , Kontos Christos K. , Adamopoulos Panagiotis G. , Nakou Evangelia , Vakalopoulou Sofia , Garypidou Vassilia , Papaioannou Maria , Hatjiharissi Evdoxia , Papadaki Helen A. , Spanoudakis Emmanuil , Pappa Vassiliki , Scorilas Andreas , Tsatalas Constantinos , Kotsianidis Ioannis
Published: April 2023

Mutations analysis of the TET2 and TP53 coding regions using Next-Generation Sequencing (NGS)
Supplementary table S3 from Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy
Authors: Lee Hye Won , Lee Jung-il , Lee Se Jeong , Cho Hyun Jung , Song Hye Jin , Jeong Da Eun , Seo Yun Jee , Shin Sang , Joung Je-Gun , Kwon Yong-Jun , Choi Yoon-La , Park Woong-Yang , Lee Hyun Moo , Seol Ho Jun , Shim Young Mog , Joo Kyeung Min , Nam Do-Hyun
Published: April 2023

Supplementary table S3. Clinicopathological characteristics and in vivo tumorigenicity of primary NSCLC cases.
Supplementary table S1 from Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy
Authors: Lee Hye Won , Lee Jung-il , Lee Se Jeong , Cho Hyun Jung , Song Hye Jin , Jeong Da Eun , Seo Yun Jee , Shin Sang , Joung Je-Gun , Kwon Yong-Jun , Choi Yoon-La , Park Woong-Yang , Lee Hyun Moo , Seol Ho Jun , Shim Young Mog , Joo Kyeung Min , Nam Do-Hyun
Published: April 2023

Supplementary table S1. Clinicopathologic characteristics of primary and brain metastatic non-small cell lung cancer (NSCLC) patients
Supplementary Figure S2 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
Authors: Miltiades Paraskevi , Lamprianidou Eleftheria , Vassilakopoulos Theodoros P. , Papageorgiou Sotirios G. , Galanopoulos Athanasios G. , Kontos Christos K. , Adamopoulos Panagiotis G. , Nakou Evangelia , Vakalopoulou Sofia , Garypidou Vassilia , Papaioannou Maria , Hatjiharissi Evdoxia , Papadaki Helen A. , Spanoudakis Emmanuil , Pappa Vassiliki , Scorilas Andreas , Tsatalas Constantinos , Kotsianidis Ioannis
Published: April 2023

Significantly higher basal levels of Stat3 in patients with poor-risk cytogenetics.
Supplementary Figure 2 from Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma
Authors: Andrews Miles C. , Turner Natalie , Boyd Janis , Roberts Andrew W. , Grigg Andrew P. , Behren Andreas , Cebon Jonathan
Published: April 2023

Supplementary Figure 2. Additional K562 BCR-ABL Western Blot densitometry.
Supplementary tables S1-S6 from The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Authors: Liu Li , Mayes Patrick A. , Eastman Stephen , Shi Hong , Yadavilli Sapna , Zhang Tianqian , Yang Jingsong , Seestaller-Wehr Laura , Zhang Shu-Yun , Hopson Chris , Tsvetkov Lyuben , Jing Junping , Zhang Shu , Smothers James , Hoos Axel
Published: April 2023

Supplementary tables S1-S6. Tumor gene expression data
Supplementary Figure S5 from Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin
Authors: Jin Yanli , Nie Danian , Li Juan , Du Xin , Lu Yuhong , Li Yangqiu , Liu Chang , Zhou Jingfeng , Pan Jingxuan
Published: April 2023

Pharmacological inhibition of AXL reduces the percentage of CML stem cells in vivo.
Supplementary Table S3 from Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer
Authors: Kalina Jennifer L. , Neilson David S. , Lin Yen-Yi , Hamilton Phineas T. , Comber Alexandra P. , Loy Emma M.H. , Sahinalp S. Cenk , Collins Colin C. , Hach Faraz , Lum Julian J.
Published: April 2023

List of patient CASQ
Supplementary Figure S1 from Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin
Authors: Jin Yanli , Nie Danian , Li Juan , Du Xin , Lu Yuhong , Li Yangqiu , Liu Chang , Zhou Jingfeng , Pan Jingxuan
Published: April 2023

Overexpressed AXL increases stem cell properties and contributes to IM-resistance in CML.
Supplemental Figures S1, S2, and S3 from Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma
Authors: Xi Liqiang , Pham Trinh Hoc-Tran , Payabyab Eden C. , Sherry Richard M. , Rosenberg Steven A. , Raffeld Mark
Published: April 2023

Fig. S1. castPCR{trade mark, serif} design, analytical sensitivity and specificity, and cfDNA measurements Fig. S2. Mutational analysis of tumor specimens from 93 NCI TIL patients Fig. S3. Cases excluded from pattern analysis
Supplemental Material from 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors
Authors: Bensch Frederike , Lamberts Laetitia E. , Smeenk Michaël M. , Jorritsma-Smit Annelies , Lub-de Hooge Marjolijn N. , Terwisscha van Scheltinga Anton G.T. , de Jong Johan R. , Gietema Jourik A. , Schröder Carolien P. , Thomas Marlene , Jacob Wolfgang , Abiraj Keelara , Adessi Celine , Meneses-Lorente Georgina , James Ian , Weisser Martin , Brouwers Adrienne H. , de Vries Elisabeth G.E.
Published: April 2023

Supplemental Figures and Tables
Supplementary Materials from Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Authors: Felsberg Jörg , Hentschel Bettina , Kaulich Kerstin , Gramatzki Dorothee , Zacher Angela , Malzkorn Bastian , Kamp Marcel , Sabel Michael , Simon Matthias , Westphal Manfred , Schackert Gabriele , Tonn Jörg C. , Pietsch Torsten , von Deimling Andreas , Loeffler Markus , Reifenberger Guido , Weller Michael
Published: April 2023

Supplementary Table 1. Overview of the individual survival times, MGMT promoter methylation status and results of EGFRvIII testing by immunohistochemistry (IHC) or reverse transcription-PCR (RT-PCR) in primary tumors (PT) and recurrent tumors (RT) of 106 patients with newly diagnosed EGFR-amplified glioblastomas, IDH-wildtype. PFS, progression-free survival; OS, overall survival; n.d., not determined; * deceased patients; ** no progression documented; {section sign} excluded for Kaplan-Meier analyses because EGFRvIII was determined at second recurrence. Supplementary Table 2. Overview of individual survival times, MGMT promoter methylation status and results of EGFRvIII testing by immunohistochemistry (IHC) or reverse transcription-PCR (RT-PCR) in primary tumors (PT) and recurrent tumors (RT) of 33 patients with newly diagnosed IDH-wildtype, EGFR-non-amplified glioblastomas. N.d., not determined. * Deceased patients. Supplementary Table 3. Overview of the EGFR single nucleotide variants (SNVs) detected by next generation sequencing (NGS) in primary (PT) and recurrent (RT) glioblastomas of 27 patients. Mutant allele frequencies in percent are provided for each single nucleotide variant (SNV). Supplementary Table 4. Overview of the validation cohort of 150 TCGA patients with IDH-wildtype glioblastoma (GBM). Supplementary Figure 1. Demonstration of regional heterogeneity of EGFRvIII expression in an EGFR-amplified primary glioblastoma, IDH-wildtype (patient 96). Supplementary Figure 2. EGFRvIII expression and MGMT promoter methylation status and survival outcome in 77 patients with EGFR-amplified glioblastomas treated with radiotherapy and temozolomide chemotherapy. Supplementary Figure 3. Survival of patients with EGFR-amplified glioblastomas, IDH-wildtype, according to the EGFRvIII status in the subgroups of patients who received second surgery (52 patients) or did not receive second surgery (54 patients). Supplementary Figure 4. Survival of 27 German Glioma Network (GGN) patients with glioblastoma, IDH-wildtype, according to presence (9 patients) or absence (18 patients) of at least one EGFR single nucleotide variant (SNV) as detected by NGS of the EGFR coding sequence. Supplementary Figure 5. Survival of TCGA patients with glioblastoma, IDH-wildtype, according to EGFR amplification, presence of at least one EGFR single nucleotide variant (SNV), and EGFRvIII positivity.
supplementary file 1 from Multilayered Omics-Based Analysis of a Head and Neck Cancer Model of Cisplatin Resistance Reveals Intratumoral Heterogeneity and Treatment-Induced Clonal Selection
Authors: Niehr Franziska , Eder Theresa , Pilz Tanja , Konschak Robert , Treue Denise , Klauschen Frederick , Bockmayr Michael , Türkmen Seval , Jöhrens Korinna , Budach Volker , Tinhofer Ingeborg
Published: April 2023

List of 327 genes covered by tNGS
Supplementary Table S3: A hypothetical example of an updated DTP for Cohorts 7 to 9 in the Viola trial from Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making
Authors: Yap Christina , Billingham Lucinda J. , Cheung Ying Kuen , Craddock Charlie , O'Quigley John
Published: April 2023

A hypothetical example of an updated DTP for Cohorts 7 to 9 in the Viola trial with the final recommended MTD. This is based on observing DLT outcomes of 0/3 DLT at Dose 0, 1/3 DLT at Dose 1 and 0/3 DLT at Dose 1 for Cohorts 1 to 3 respectively (pathway 5 in Table 2), followed by 1/3 DLT at Dose 2, 0/3 DLT at Dose 1 and 2/2 DLT at Dose 2 for Cohorts 4 to 6 respectively (pathway 19 in Supplementary Table S3).
Supplementary Table S1: Key alterations in pathway components from Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors
Authors: Tripathy Debu , Bardia Aditya , Sellers William R.
Published: April 2023

Key alterations in cyclin-CDK4/6-p16-Rb pathway components across tumor types.
Supplementary table 3a from Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
Authors: Ock Chan-Young , Keam Bhumsuk , Kim Sehui , Lee Ju-Seog , Kim Miso , Kim Tae Min , Jeon Yoon Kyung , Kim Dong-Wan , Chung Doo Hyun , Heo Dae Seog
Published: April 2023

Supplementary table 3a. Specific somatic mutation of cancer driver genes to predict tumor microenvironment immune types
Supplementary Figure Legend from Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody
Authors: Dominguez George A. , Condamine Thomas , Mony Sridevi , Hashimoto Ayumi , Wang Fang , Liu Qin , Forero Andres , Bendell Johanna , Witt Robert , Hockstein Neil , Kumar Prasanna , Gabrilovich Dmitry I.
Published: April 2023

Supplementary Figure Legend
Figure S1,Table S1 from Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals
Authors: Shayan Gulidanna , Kansy Benjamin A. , Gibson Sandra P. , Srivastava Raghvendra M. , Bryan James Kyle , Bauman Julie E. , Ohr James , Kim Seungwon , Duvvuri Umamaheswar , Clump David A. , Heron Dwight E. , Johnson Jonas T. , Hershberg Robert M. , Ferris Robert L.
Published: April 2023

Supplementary figure S1: IL-10, IL-1RA and Eotaxin plasma concentration in patients pre- vs. post-treatment with Cetuximab plus motolimod. Supplementary table S1: 95% confidence interval for figure 5 comparing pre vs post treatment expression changes of TIGIT, PD-1, CTLA-4 and CD27.
Figure S2 from Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome
Authors: Derks Jules L. , Leblay Noémie , Thunnissen Erik , van Suylen Robert Jan , den Bakker Michael , Groen Harry J.M. , Smit Egbert F. , Damhuis Ronald , van den Broek Esther C. , Charbrier Amélie , Foll Matthieu , McKay James D. , Fernandez-Cuesta Lynnette , Speel Ernst-Jan M. , Dingemans Anne-Marie C.
Published: April 2023

Progression-free survival for subtypes of chemotherapy in panel-consensus LCNEC with A) RB1 wild-type*; B) RB1 mutation; C) H-score {greater than or equal to}50 for RB1* IHC; D) H-score <50 for RB1 IHC; E) H-score <50 for P16 IHC; F) H-score {greater than or equal to}50 for RB1* or <50 for P16 on IHC analysis. Abbreviations: No, number of. *Case 162 excluded from analyses.
Supplementary Figure legends from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Authors: Dong Zhong-Yi , Zhong Wen-Zhao , Zhang Xu-Chao , Su Jian , Xie Zhi , Liu Si-Yang , Tu Hai-Yan , Chen Hua-Jun , Sun Yue-Li , Zhou Qing , Yang Jin-Ji , Yang Xue-Ning , Lin Jia-Xin , Yan Hong-Hong , Zhai Hao-Ran , Yan Li-Xu , Liao Ri-Qiang , Wu Si-Pei , Wu Yi-Long
Published: April 2023

Supplementary Figure legends
supplemental legend from Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
Authors: Guedes Liana B. , Morais Carlos L. , Almutairi Fawaz , Haffner Michael C. , Zheng Qizhi , Isaacs John T. , Antonarakis Emmanuel S. , Lu Changxue , Tsai Harrison , Luo Jun , De Marzo Angelo M. , Lotan Tamara L.
Published: April 2023

supplemental legend
Figure S3 from Degalactotigonin, a Natural Compound from Solanum nigrum L., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway
Authors: Zhao Zhiqiang , Jia Qiang , Wu Man-Si , Xie Xianbiao , Wang Yongqian , Song Guohui , Zou Chang-Ye , Tang Qinglian , Lu Jinchang , Huang Gang , Wang Jin , Lin De-Chen , Koeffler H. Phillip , Yin Jun-Qiang , Shen Jingnan
Published: April 2023

Pathological changes were observed in vital organs (heart, livers, kidney and lung) from mice treated with DGT, as detected by HE staining.
Figure S2 from Degalactotigonin, a Natural Compound from Solanum nigrum L., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway
Authors: Zhao Zhiqiang , Jia Qiang , Wu Man-Si , Xie Xianbiao , Wang Yongqian , Song Guohui , Zou Chang-Ye , Tang Qinglian , Lu Jinchang , Huang Gang , Wang Jin , Lin De-Chen , Koeffler H. Phillip , Yin Jun-Qiang , Shen Jingnan
Published: April 2023

The effects of DGT on the mice weight.
Supplemental Figures S1-S6 from GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial
Authors: Van Damme Pierre , Bouillette-Marussig Myriam , Hens Annick , De Coster Ilse , Depuydt Christophe , Goubier Anne , Van Tendeloo Viggo , Cools Nathalie , Goossens Herman , Hercend Thierry , Timmerman Benedikt , Bissery Marie-Christine
Published: April 2023

Mean background corrected ELISpot magnitudes
Supplemental Figure 4 from Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma
Authors: Chicard Mathieu , Boyault Sandrine , Colmet Daage Leo , Richer Wilfrid , Gentien David , Pierron Gaelle , Lapouble Eve , Bellini Angela , Clement Nathalie , Iacono Isabelle , Bréjon Stéphanie , Carrere Marjorie , Reyes Cécile , Hocking Toby , Bernard Virginie , Peuchmaur Michel , Corradini Nadège , Faure-Conter Cécile , Coze Carole , Plantaz Dominique , Defachelles Anne Sophie , Thebaud Estelle , Gambart Marion , Millot Frédéric , Valteau-Couanet Dominique , Michon Jean , Puisieux Alain , Delattre Olivier , Combaret Valérie , Schleiermacher Gudrun
Published: April 2023

Determination of IGR1R status in genomic DNA from the primary tumor and cfDNA using qPCR in cases 3 and 17
Supplemental Figure 2 from Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma
Authors: Chicard Mathieu , Boyault Sandrine , Colmet Daage Leo , Richer Wilfrid , Gentien David , Pierron Gaelle , Lapouble Eve , Bellini Angela , Clement Nathalie , Iacono Isabelle , Bréjon Stéphanie , Carrere Marjorie , Reyes Cécile , Hocking Toby , Bernard Virginie , Peuchmaur Michel , Corradini Nadège , Faure-Conter Cécile , Coze Carole , Plantaz Dominique , Defachelles Anne Sophie , Thebaud Estelle , Gambart Marion , Millot Frédéric , Valteau-Couanet Dominique , Michon Jean , Puisieux Alain , Delattre Olivier , Combaret Valérie , Schleiermacher Gudrun
Published: April 2023

Comparison of recurrent SCA seen by aCGH versus cfDNA Oncoscan® analysis
Supplementary Table S1 from A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA
Authors: Ooki Akira , Maleki Zahra , Tsay Jun-Chieh J. , Goparaju Chandra , Brait Mariana , Turaga Nitesh , Nam Hae-Seong , Rom William N. , Pass Harvey I. , Sidransky David , Guerrero-Preston Rafael , Hoque Mohammad Obaidul
Published: April 2023

Supplementary Table S1.The PCR condition and sequences of the primer and the fluorescent probe used in this study.
Supplemental Data from A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Authors: Gojo Ivana , Beumer Jan H. , Pratz Keith W. , McDevitt Michael A. , Baer Maria R. , Blackford Amanda L. , Smith B. Douglas , Gore Steven D. , Carraway Hetty E. , Showel Margaret M. , Levis Mark J. , Dezern Amy E. , Gladstone Douglas E. , Ji Jiuping Jay , Wang Lihua , Kinders Robert J. , Pouquet Marie , Ali-Walbi Ismail , Rudek Michelle A. , Poh Weijie , Herman James G. , Karnitz Larry M. , Kaufmann Scott H. , Chen Alice , Karp Judith E.
Published: April 2023

Table S1. Changes in Proportion (%) of γH2AX-Positive Cells in Peripheral Blood upon Veliparib and Veliparib/Temozolomide Treatment Figure S1. FANCD2 monoubiquitination following ex vivo melphalan treatment of patient bone marrow cells Figure S2.Pretreatment levels of PARP1 and MGMT Figure S3.Pretreatment MGMT promoter methylation in patient peripheral blood (PB) or bone marrow (BM) AML cells Figure S4. PARP inhibition in peripheral blood cells
Supplementary data from Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Authors: Saloura Vassiliki , Fatima Aiman , Zewde Makda , Kiyotani Kazuma , Brisson Ryan , Park Jae-Hyun , Ikeda Yuji , Vougiouklakis Theodore , Bao Riyue , Khattri Arun , Seiwert Tanguy , Cipriani Nicole , Lingen Mark , Vokes Everett , Nakamura Yusuke
Published: April 2023

Supplementary Figure 1. TCR-β DI in HPV-positive patients (excluding smokers with {greater than or equal to}10packyear history) versus HPV-negative patients (excluding patients with <10pack-year history) (Mann-Whitney U-test, p=0.004). Supplementary Figure 2. Sum of percentages of top 10 CDR3 clonotypes in HPV-positive versus HPV-negative tumors (Mann-Whitney U-test, p=0.01). Supplementary Figure 3. RT-PCR results for CTLA4, PD-1, IDO1, PD-L1, PD-L2, CD206 and FOXP3/CD4 ratio in HPV-positive versus HPV-negative tumors (Mann-Whitney U-test). Supplementary Figure 4. TCR-β DI, recurrence-free survival and overall survival Kaplan-Meier curves. Supplementary Figure 5. TCR-β DI, T-stage, N-stage and tumor localization (Mann-Whitney U- test). Supplementary Figure 6. Significant correlations of GRZB and PRF1 with B7-H3, CD206, FOXP3 and CTLA4 using RT-PCR in tissues from 44 patients with locoregionally advanced SCCHN. Pearson''s correlation co-efficients and p-values are shown for each graph. Supplementary Figure 7. Significant correlations of CD4, CTLA4 and FOXP3 with TCR-β DI using RT-PCR and TCR sequencing in tissues from 43 patients with locoregionally advanced SCCHN. Pearson''s correlation co-efficients and p-values are shown for each graph. Supplementary Figure 8. HLA-A mRNA levels in HPV-positive versus HPV-negative patients (n=44) and association of HLA-A mRNA with TCR-β DI. HLA-A expression (logarithmic scale) was divided by median (T1-T2) and the TCR-β DI (logarithmic scale) was plotted against the HLA-A expression categories. Supplementary Table 1. Univariate and multivariate Cox-regression analysis of overall survival for immune markers and HPV status, tumor and nodal stage.
Supplementary Figures from Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung
Authors: Miyoshi Tomohiro , Umemura Shigeki , Matsumura Yuki , Mimaki Sachiyo , Tada Satoshi , Makinoshima Hideki , Ishii Genichiro , Udagawa Hibiki , Matsumoto Shingo , Yoh Kiyotaka , Niho Seiji , Ohmatsu Hironobu , Aokage Keiju , Hishida Tomoyuki , Yoshida Junji , Nagai Kanji , Goto Koichi , Tsuboi Masahiro , Tsuchihara Katsuya
Published: April 2023

Supplementary Figure 1: Representative example of tissue microarray (TMA) punched out from a combined large-cell neuroendocrine carcinoma (LCNEC) with adenocarcinoma. Supplementary Figure 2: Validation of five mutations on the PI3K/AKT/mTOR pathway by Sanger sequencing (LCNEC 68c: PIK3CA E545K, LCNEC 9c: PTEN K342*, LCNEC 13c: PTEN S59*, LCNEC 4c: RICTOR R910H, LCNEC 11p: MTOR E2419K). Supplementary Figure 3: Correlation of gene copy number, calculated using the total depth on the covered region of each of 244 targeted genes and those obtained from the Oncomine® Cancer Research Panel (OCP). Supplementary Figure 4: Validation of the copy number gains or amplifications of 13 samples (8 LCNEC samples, 1 SCLC biopsy samples and 4 SCLC surgically resected cases) for MYCL1, MYC and FGFR1 by a quantitative real-time polymerase chain reaction (qPCR). Supplementary Figure 5: Overview of the key driver alterations and other activating alterations in small cell lung cancer (SCLC). Genetic alterations in the PI3K/AKT/mTOR pathway were detected in 24 (17%) of the tumors: PIK3CA (4%), PTEN (6%), AKT2 (2%) and RICTOR (6%). Copy number gains of each MYC family member were mutually exclusive. Supplementary Figure 6: Relationship between RB1 mutation and IHC staining of RB and p16. The mutual exclusivity of the protein expression between RB and p16 was distinct. Supplementary Figure 7: Relationship between genetic alteration and protein expression in large-cell neuroendocrine carcinoma (LCNEC) of the lung. Comparison of the over expression of receptor tyrosine kinases (RTKs) with the genetic alterations in resected LCNEC specimens (51 of 65 resected cases) revealed no significant relationship between strongly positive RTKs (KIT, EGFR, IGF1R, KDR, ERBB2) expression and genetic alterations.
Supplementary Figures from LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab
Authors: Bonanno Laura , De Paoli Angela , Zulato Elisabetta , Esposito Giovanni , Calabrese Fiorella , Favaretto Adolfo , Santo Antonio , Conte Alessandro Del , Chilosi Marco , Oniga Francesco , Sozzi Gabriella , Moro Massimo , Ciccarese Francesco , Nardo Giorgia , Bertorelle Roberta , Candiotto Cinzia , De Salvo Gian Luca , Amadori Alberto , Conte PierFranco , Indraccolo Stefano
Published: April 2023

Bonanno L. et al. Supplementary Figures
Supplementary results from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
Authors: Castiello Luciano , Sabatino Marianna , Ren Jiaqiang , Terabe Masaki , Khuu Hanh , Wood Lauren V. , Berzofsky Jay A. , Stroncek David F.
Published: April 2023

Additional Analysis not included in the main text
Table S7 from The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma
Authors: Cooke Susanna L. , Ennis Darren , Evers Lisa , Dowson Suzanne , Chan Mei Yen , Paul James , Hirschowitz Lynn , Glasspool Rosalind M. , Singh Naveena , Bell Sarah , Day Elizabeth , Kochman Agata , Wilkinson Nafisa , Beer Philip , Martin Sancha , Millan David , Biankin Andrew V. , McNeish Iain A.
Published: April 2023

Concordance of alterations in cases with multiple SCC samples
Supplementary Figure 5 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
Authors: Lamberts Laetitia E. , Koch Maximillian , de Jong Johannes S. , Adams Arthur L.L. , Glatz Jürgen , Kranendonk Mariëtte E.G. , Terwisscha van Scheltinga Anton G.T. , Jansen Liesbeth , de Vries Jakob , Lub-de Hooge Marjolijn N. , Schröder Carolien P. , Jorritsma-Smit Annelies , Linssen Matthijs D. , de Boer Esther , van der Vegt Bert , Nagengast Wouter B. , Elias Sjoerd G. , Oliveira Sabrina , Witkamp Arjen J. , Mali Willem P.Th.M. , Van der Wall Elsken , van Diest Paul J. , de Vries Elisabeth G.E. , Ntziachristos Vasilis , van Dam Gooitzen M.
Published: April 2023

Co-localization of Bevacizumab-IRDye800CW, hematoxylin / eosin (H/E), VEGF-A, Collagen and CD34 in Ductal Carcinoma In Situ (DCIS).
Table S3 from Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
Authors: Hijioka Susumu , Hosoda Waki , Matsuo Keitaro , Ueno Makoto , Furukawa Masayuki , Yoshitomi Hideyuki , Kobayashi Noritoshi , Ikeda Masafumi , Ito Tetsuhide , Nakamori Shoji , Ishii Hiroshi , Kodama Yuzo , Morizane Chigusa , Okusaka Takuji , Yanagimoto Hiroaki , Notohara Kenji , Taguchi Hiroki , Kitano Masayuki , Yane Kei , Maguchi Hiroyuki , Tsuchiya Yoshiaki , Komoto Izumi , Tanaka Hiroki , Tsuji Akihito , Hashigo Syunpei , Kawaguchi Yoshiaki , Mine Tetsuya , Kanno Atsushi , Murohisa Go , Miyabe Katsuyuki , Takagi Tadayuki , Matayoshi Nobutaka , Yoshida Tsukasa , Hara Kazuo , Imamura Masayuki , Furuse Junji , Yatabe Yasushi , Mizuno Nobumasa
Published: April 2023

Supplementary Table S3. Factors related to overall survival
Supplementary material from Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade
Authors: Moesta Achim K. , Cooke Keegan , Piasecki Julia , Mitchell Petia , Rottman James B. , Fitzgerald Karen , Zhan Jinghui , Yang Becky , Le Tiep , Belmontes Brian , Ikotun Oluwatayo F. , Merriam Kim , Glaus Charles , Ganley Kenneth , Cordover David H. , Boden Andrea M. , Ponce Rafael , Beers Courtney , Beltran Pedro J.
Published: April 2023

Supp Figures S1 to S6 and Supp Tables S1 to S2
Figure S6 from Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Authors: Kapoor Shivani , Natarajan Karthika , Baldwin Patrick R. , Doshi Kshama A. , Lapidus Rena G. , Mathias Trevor J. , Scarpa Mario , Trotta Rossana , Davila Eduardo , Kraus Manfred , Huszar Dennis , Tron Adriana E. , Perrotti Danilo , Baer Maria R.
Published: April 2023

AZD1208 and quizartinib co-treatment does not increase celluar ROS generation, but increases mitochondrial ROS generation.
table S5 from PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Authors: Tarantelli Chiara , Gaudio Eugenio , Arribas Alberto J. , Kwee Ivo , Hillmann Petra , Rinaldi Andrea , Cascione Luciano , Spriano Filippo , Bernasconi Elena , Guidetti Francesca , Carrassa Laura , Pittau Roberta Bordone , Beaufils Florent , Ritschard Reto , Rageot Denise , Sele Alexander , Dossena Barbara , Rossi Francesca Maria , Zucchetto Antonella , Taborelli Monica , Gattei Valter , Rossi Davide , Stathis Anastasios , Stussi Georg , Broggini Massimo , Wymann Matthias P. , Wicki Andreas , Zucca Emanuele , Cmiljanovic Vladimir , Fabbro Doriano , Bertoni Francesco
Published: April 2023

Phosphoproteins changes induced by PQR309 in B cell lymphoma cell lines revealed using Pathscan Akt Signaling Antibody Array Kit.
Supplementary Tables and Figures legend from The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Authors: Bozovic-Spasojevic Ivana , Zardavas Dimitrios , Brohée Sylvain , Ameye Lieveke , Fumagalli Debora , Ades Felipe , de Azambuja Evandro , Bareche Yacine , Piccart Martine , Paesmans Marianne , Sotiriou Christos
Published: April 2023

Supplementary Tables and Figures legend
Supplementary text from The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer
Authors: Rebello Richard J. , Kusnadi Eric , Cameron Donald P. , Pearson Helen B. , Lesmana Analia , Devlin Jennifer R. , Drygin Denis , Clark Ashlee K. , Porter Laura , Pedersen John , Sandhu Shahneen , Risbridger Gail P. , Pearson Richard B. , Hannan Ross D. , Furic Luc
Published: April 2023

Supplementary Materials and methods
Supplemental Table 1-2 from Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement
Authors: Tang Chad , Sherman Steven I. , Price Mellanie , Weng Jun , Davis Suzanne E. , Hong David S. , Yao James C. , Buzdar Aman , Wilding George , Lee J. Jack
Published: April 2023

Supplemental Tables 1-2
Figure S2 from LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis
Authors: Dorneburg Carmen , Fischer Matthias , Barth Thomas F.E. , Mueller-Klieser Wolfgang , Hero Barbara , Gecht Judith , Carter Daniel R. , de Preter Katleen , Mayer Benjamin , Christner Lisa , Speleman Frank , Marshall Glenn M. , Debatin Klaus-Michael , Beltinger Christian
Published: April 2023

MYCN and HIF-1α do not cooperate in inducing key enzymes of the Warburg effect
Table S3 from Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer
Authors: Post Annemarie E.M. , Smid Marcel , Nagelkerke Anika , Martens John W.M. , Bussink Johan , Sweep Fred C.G.J. , Span Paul N.
Published: April 2023

Clinicopathological characteristics of all patients in the Radboudumc cohort and comparison between groups that did or did not receive radiotherapy
Supp Figure 2 from TFAP2E Methylation and Expression Status Does Not Predict Response to 5-FU-based Chemotherapy in Colorectal Cancer
Authors: Murcia Oscar , Jover Rodrigo , Egoavil Cecilia , Perez-Carbonell Lucia , Juárez Miriam , Hernández-Illán Eva , Rojas Estefania , Alenda Cristina , Balaguer Francesc , Andreu Montserrat , Llor Xavier , Castells Antoni , Boland C. Richard , Goel Ajay
Published: April 2023

Supplementary Figure 2. Methylation analysis of TFAP2E CpG islands in CRC tissues. Calculation of cutoff value of TFAP2E Intron 3 methylation. Results comparing methylation of the TFAP2E CpG1 (Promoter/Exon 1) and CpG2 (Intron 3) in CRC tissues (N=50) by (A) Bisulfite pyrosequencing (% Methylation) (B-C) Bisulfite pyrosequencing results of TFAP2E Intron 3 methylation in normal colon mucosa from healthy subjects N-N (N=21); and CRC patients-matched tumor-and non-tumor samples N-C (N=41);(N=41). (D) Whitin-subject Receiver Operating Characteristics (ROC) analysis performed on measured TFAP2E % (percentage of methylation) values of patient-matched tumor- (N-N; N=21) and non-tumor (N-C; N=41) samples, respectively. The area under the ROC-curve was calculated as 0.73 (95% CI:0.62-0.82), indicating that the probability of observing a higher TFAP2E value in a tumor-sample of a patient compared to its related non-tumor sample is about 73%.
Table S1 from A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma
Authors: Gedeon Patrick C. , Schaller Teilo H. , Chitneni Satish K. , Choi Bryan D. , Kuan Chien-Tsun , Suryadevara Carter M. , Snyder David J. , Schmittling Robert J. , Szafranski Scott E. , Cui Xiuyu , Healy Patrick N. , Herndon James E. , McLendon Roger E. , Keir Stephen T. , Archer Gary E. , Reap Elizabeth A. , Sanchez-Perez Luis , Bigner Darell D. , Sampson John H.
Published: April 2023

Table S1 - Construct design, expression parameters and associated binding kinetic and purification yield outcomes for each of the constructs tested as part of this study.
Supplementary Table S1 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
Authors: Luk Iris Sze Ue , Shrestha Raunak , Xue Hui , Wang Yuwei , Zhang Fang , Lin Dong , Haegert Anne , Wu Rebecca , Dong Xin , Collins Colin C. , Zoubeidi Amina , Gleave Martin E. , Gout Peter W. , Wang Yuzhuo
Published: April 2023

The qPCR primer sequences used
Figure S1 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Authors: Yonesaka Kimio , Haratani Koji , Takamura Shiki , Sakai Hitomi , Kato Ryoji , Takegawa Naoki , Takahama Takayuki , Tanaka Kaoru , Hayashi Hidetoshi , Takeda Masayuki , Kato Sigeki , Maenishi Osamu , Sakai Kazuko , Chiba Yasutaka , Okabe Takafumi , Kudo Keita , Hasegawa Yoshikazu , Kaneda Hiroyasu , Yamato Michiko , Hirotani Kenji , Miyazawa Masaaki , Nishio Kazuto , Nakagawa Kazuhiko
Published: April 2023

The B7-H3 staining pattern for diagnosis
Supplementary table S2 from Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk Groups
Authors: van Kessel Kim E.M. , van der Keur Kirstin A. , Dyrskjøt Lars , Algaba Ferran , Welvaart Naeromy Y.C. , Beukers Willemien , Segersten Ulrika , Keck Bastian , Maurer Tobias , Simic Tatjana , Horstmann Marcus , Grimm Marc-Oliver , Hermann Gregers G. , Mogensen Karin , Hartmann Arndt , Harving Niels , Petersen Astrid C. , Jensen Jørgen B. , Junker Kerstin , Boormans Joost L. , Real Francisco X. , Malats Núria , Malmström Per-Uno , Ørntoft Torben F. , Zwarthoff Ellen C.
Published: April 2023

Supplementary Table S2. Cut-offs for dichotomization of the methylation marker results were chosen based on the desired sensitivity-specificity trade-off for progression to MIBC as visualized by the receiver-operating characteristic curve (ROC curve); the point on the curve closest to the upper left corner.
Table S1 from Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis
Authors: Aushev Vasily N. , Lee Eunjee , Zhu Jun , Gopalakrishnan Kalpana , Li Qian , Teitelbaum Susan L. , Wetmur James , Degli Esposti Davide , Hernandez-Vargas Hector , Herceg Zdenko , Parada Humberto , Santella Regina M. , Gammon Marilie D. , Chen Jia
Published: April 2023

Table S1 (pdf file). Full demographic and clinical characteristics of profiled patients and the LIBCSP parent subset.
Supplemental Methods from Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis
Authors: Aushev Vasily N. , Lee Eunjee , Zhu Jun , Gopalakrishnan Kalpana , Li Qian , Teitelbaum Susan L. , Wetmur James , Degli Esposti Davide , Hernandez-Vargas Hector , Herceg Zdenko , Parada Humberto , Santella Regina M. , Gammon Marilie D. , Chen Jia
Published: April 2023

Supplemental Methods
Legends for Supplemental Tables from Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis
Authors: Aushev Vasily N. , Lee Eunjee , Zhu Jun , Gopalakrishnan Kalpana , Li Qian , Teitelbaum Susan L. , Wetmur James , Degli Esposti Davide , Hernandez-Vargas Hector , Herceg Zdenko , Parada Humberto , Santella Regina M. , Gammon Marilie D. , Chen Jia
Published: April 2023

Legends for Supplemental Tables
Table S9 from High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma
Authors: Sandulache Vlad C. , Michikawa Chieko , Kataria Pranav , Gleber-Netto Frederico O. , Bell Diana , Trivedi Sanchit , Rao Xiayu , Wang Jing , Zhao Mei , Jasser Samar , Myers Jeffrey N. , Pickering Curtis R.
Published: April 2023

Table S9 from High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma
Table S8 from High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma
Authors: Sandulache Vlad C. , Michikawa Chieko , Kataria Pranav , Gleber-Netto Frederico O. , Bell Diana , Trivedi Sanchit , Rao Xiayu , Wang Jing , Zhao Mei , Jasser Samar , Myers Jeffrey N. , Pickering Curtis R.
Published: April 2023

Table S8 from High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma
Figure S5 from Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis
Authors: Aushev Vasily N. , Lee Eunjee , Zhu Jun , Gopalakrishnan Kalpana , Li Qian , Teitelbaum Susan L. , Wetmur James , Degli Esposti Davide , Hernandez-Vargas Hector , Herceg Zdenko , Parada Humberto , Santella Regina M. , Gammon Marilie D. , Chen Jia
Published: April 2023

Fig. S5. Survival curves among the LIBCSP patients, stratified by ROR group (left panel) and molecular subtype (right panel).
Supplementary Figure and Table Legends from High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma
Authors: Sandulache Vlad C. , Michikawa Chieko , Kataria Pranav , Gleber-Netto Frederico O. , Bell Diana , Trivedi Sanchit , Rao Xiayu , Wang Jing , Zhao Mei , Jasser Samar , Myers Jeffrey N. , Pickering Curtis R.
Published: April 2023

Supplementary Figure and Table Legends from High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma
Supplementary Methods from Thy1-Targeted Microbubbles for Ultrasound Molecular Imaging of Pancreatic Ductal Adenocarcinoma
Authors: Abou-Elkacem Lotfi , Wang Huaijun , Chowdhury Sayan M. , Kimura Richard H. , Bachawal Sunitha V. , Gambhir Sanjiv S. , Tian Lu , Willmann Jürgen K.
Published: April 2023

Supplementary Methods
Supplementary Table 1 from Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study
Authors: Pietrantonio Filippo , Fucà Giovanni , Morano Federica , Gloghini Annunziata , Corso Simona , Aprile Giuseppe , Perrone Federica , De Vita Ferdinando , Tamborini Elena , Tomasello Gianluca , Gualeni Ambra Vittoria , Ongaro Elena , Busico Adele , Giommoni Elisa , Volpi Chiara Costanza , Laterza Maria Maddalena , Corallo Salvatore , Prisciandaro Michele , Antista Maria , Pellegrinelli Alessandro , Castagnoli Lorenzo , Pupa Serenella M. , Pruneri Giancarlo , de Braud Filippo , Giordano Silvia , Cremolini Chiara , Di Bartolomeo Maria
Published: April 2023

Prevalence of alterations not included in the AMNESIA panel, reported by means of NGS from resistant (cases) versus sensitive (controls) patients.
Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin from Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin
Authors: Wang Xu , Beitler Jonathan J. , Huang Wen , Chen Guo , Qian Guoqing , Magliocca Kelly , Patel Mihir R. , Chen Amy Y. , Zhang Jun , Nannapaneni Sreenivas , Kim Sungjin , Chen Zhengjia , Deng Xingming , Saba Nabil F. , Chen Zhuo Georgia , Arbiser Jack L. , Shin Dong M.
Published: April 2023

Supplementary Fig. 1. Radiation induces survivin expression in TU686 cells. Supplementary Fig. 2. Effects of survivin siRNA and H2AX siRNA on the co-localization of survivin and H2AX. PCI-15A cells were transfected with siRNA specific for survivin or control siRNA (upper panel) and siRNA specific for H2AX or control siRNA (lower panel) (for 48h) followed by 4 Gy RT. Supplementary Table 1. Clinical Patient Characteristics Supplementary Table 2 Univariate association of Survivin WI with covariates Supplementary Table 3. Univariate DFS analysis in all patients Supplementary Table 4. Univariate Overall Survival Analysis in all Patients Supplementary Table 5. Multivariate OS analysis in all patients Supplementary Table 6. Multivariable DFS analysis in all patients
Supplementary Table from Epigenome-wide SRC-1–Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer
Authors: Ward Elspeth , Varešlija Damir , Charmsaz Sara , Fagan Ailis , Browne Alacoque L. , Cosgrove Nicola , Cocchiglia Sinéad , Purcell Siobhan P. , Hudson Lance , Das Sudipto , O'Connor Darran , O'Halloran Philip J. , Sims Andrew H. , Hill Arnold D. , Young Leonie S.
Published: April 2023

Table S2: 251 genes within 5kb of SRC-1 peak upstream of the TSS (Ensembl ID)
Fig S4 from Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation
Authors: Takagi Satoshi , Tsukamoto Shokichi , Park Jihye , Johnson Kelly E. , Kawano Yawara , Moschetta Michele , Liu Chia-Jen , Mishima Yuji , Kokubun Katsutoshi , Manier Salomon , Salem Karma Z. , Huynh Daisy , Sacco Antonio , Forward Jodi , Roccaro Aldo M. , Battinelli Elisabeth M. , Ghobrial Irene M.
Published: April 2023

Treatment of CD41 Ab reduced the platelet count in SCID-beige mice.
Fig S3 from Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation
Authors: Takagi Satoshi , Tsukamoto Shokichi , Park Jihye , Johnson Kelly E. , Kawano Yawara , Moschetta Michele , Liu Chia-Jen , Mishima Yuji , Kokubun Katsutoshi , Manier Salomon , Salem Karma Z. , Huynh Daisy , Sacco Antonio , Forward Jodi , Roccaro Aldo M. , Battinelli Elisabeth M. , Ghobrial Irene M.
Published: April 2023

Fifteen cytokines were secreted by the MM cell-mediated platelet activation.
Supplemental Fig 3 from Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
Authors: Tang Chad , Welsh James W. , de Groot Patricia , Massarelli Erminia , Chang Joe Y. , Hess Kenneth R. , Basu Sreyashi , Curran Michael A. , Cabanillas Maria E. , Subbiah Vivek , Fu Siqing , Tsimberidou Apostolia M. , Karp Daniel , Gomez Daniel R. , Diab Adi , Komaki Ritsuko , Heymach John V. , Sharma Padmanee , Naing Aung , Hong David S.
Published: April 2023

Teff Expression
Supplementary Table S2. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
Authors: Rossi Giovanna , Mu Zhaomei , Rademaker Alfred W. , Austin Laura K. , Strickland Kimberly S. , Costa Ricardo Lima Barros , Nagy Rebecca J. , Zagonel Vittorina , Taxter Timothy J. , Behdad Amir , Wehbe Firas H. , Platanias Leonidas C. , Gradishar William J. , Cristofanilli Massimo
Published: April 2023

Distribution of the previous treatments (before the ESR1 mutation detection) in the subgroup of patients with ER+ ESR1+ disease versus the patients with ER+ ESR1- disease.
Table s2 from Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance
Authors: Suenaga Masaya , Yu Jun , Shindo Koji , Tamura Koji , Almario Jose Alejandro , Zaykoski Christopher , Witmer P. Dane , Fesharakizadeh Shahriar , Borges Michael , Lennon Anne-Marie , Shin Eun-Ji , Canto Marcia Irene , Goggins Michael
Published: April 2023

Variants of unknown significance
Supplementary Table 4 from Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
Authors: Canale Matteo , Petracci Elisabetta , Delmonte Angelo , Chiadini Elisa , Dazzi Claudio , Papi Maximilian , Capelli Laura , Casanova Claudia , De Luigi Nicoletta , Mariotti Marita , Gamboni Alessandro , Chiari Rita , Bennati Chiara , Calistri Daniele , Ludovini Vienna , Crinò Lucio , Amadori Dino , Ulivi Paola
Published: April 2023

ORR and DCR observed in EGFR exon 19 deleted patients in relation to TP53 mutations
Supplementary Table 3 from Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
Authors: Canale Matteo , Petracci Elisabetta , Delmonte Angelo , Chiadini Elisa , Dazzi Claudio , Papi Maximilian , Capelli Laura , Casanova Claudia , De Luigi Nicoletta , Mariotti Marita , Gamboni Alessandro , Chiari Rita , Bennati Chiara , Calistri Daniele , Ludovini Vienna , Crinò Lucio , Amadori Dino , Ulivi Paola
Published: April 2023

Association between TP53 and EGFR mutations